Infectious Disease Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2032

Infectious Disease Diagnostics Market Summary

• The global infectious disease diagnostics market is expected to increase from USD 28,338.85 million in 2025 to USD 38,155.00 million by 2034, reflecting strong and sustained growth.
• The global infectious disease diagnostics market is growing at a CAGR of 3.41% during the forecast period from 2026 to 2034.
• The rising prevalence of infectious diseases such as tuberculosis, influenza, hepatitis, HIV, and emerging viral infections is significantly increasing the demand for rapid and accurate diagnostic solutions worldwide. At the same time, growing awareness among patients and healthcare providers, along with government-led screening and surveillance programs, is encouraging early disease detection and routine testing, thereby expanding the adoption of infectious disease diagnostics. In addition, continuous product development activities by diagnostic companies, including the launch of advanced molecular diagnostics, point-of-care testing kits, AI-enabled platforms, and multiplex assays, are improving testing accuracy, speed, and accessibility. Collectively, these factors are driving the growth of the infectious disease diagnostics market by increasing testing volumes, enhancing healthcare infrastructure, and supporting timely disease management across both developed and emerging regions.
• The leading companies operating in the infectious disease diagnostics market include Hoffmann-La Roche Ltd., Abbott Laboratories, Bio-Rad Laboratories, Inc., Danaher Corporation, Thermo Fisher Scientific Inc., QIAGEN, bioMerieux, Siemens Healthineers AG, DiaSorin S.p.A., Hologic, Inc., Sysmex Corporation, QuidelOrtho Corporation, Biosynex SA, Cardinal Health, Laboratory Corporation of America Holdings, Eurofins Scientific, InfeXn Laboratories Pvt Ltd., Aegis Sciences Corporation, Meridian Bioscience, Inc., BD, OraSure Technologies, Inc., Trinity Biotech plc, Chembio Diagnostics, Inc., Sekisui Diagnostics, PerkinElmer, Inc., GenMark Diagnostics, Inc., Seegene Inc., Fujirebio Holdings, Inc., Arkray, Inc., SD Biosensor, Inc., Mylab Discovery Solutions Pvt. Ltd., Molbio Diagnostics Pvt. Ltd., GenBody Inc., and others.
• North America is expected to dominate the infectious disease diagnostics market due to the high prevalence of infectious diseases, strong presence of leading diagnostic companies, advanced healthcare infrastructure, and increased adoption of molecular and point-of-care diagnostic technologies. In addition, favorable government initiatives, high healthcare spending, rising awareness regarding early disease detection, and continuous research and product development activities are further supporting market growth across the region.
• In the type segment of the infectious disease diagnostics market, the products category is estimated to account for the largest market share in 2025.

Factors Contributing to the Growth of the Infectious Disease Diagnostics Market

• Rising prevalence of infectious diseases: The surge in infectious diseases such as tuberculosis (TB), HIV/AIDS, hepatitis, malaria, and respiratory infections has created a pressing need for timely and accurate diagnostics. Emerging threats like COVID-19, Ebola, Zika virus, and drug-resistant bacteria have further heightened the demand for infectious disease diagnostics.
• Increased awareness and screening programs: Awareness programs are crucial in combating infectious diseases by educating communities, promoting preventive measures, and encouraging early diagnosis and treatment. Various infectious diseases have dedicated awareness programs globally, each aiming to address unique challenges.
• Increase in product development activities across the globe: The increase in product development activities is significantly boosting the overall market of infectious disease diagnostics by driving innovation, improving accuracy, and enhancing accessibility. Companies are investing heavily in developing advanced diagnostic tools, such as rapid tests, molecular diagnostics, and point-of-care testing devices, which offer quicker results and greater convenience. These innovations address the growing demand for early detection and timely treatment, crucial for managing outbreaks and reducing disease transmission.

Infectious Disease Diagnostics Market Report Segmentation

This infectious disease diagnostics market report offers a comprehensive overview of the global infectious disease diagnostics market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Type (Products {Instruments and Reagents & Kits} and Services), Technology (Molecular Diagnostics {Polymerase chain reaction (PCR), DNA Sequencing and Next-Generation Sequencing (NGS), Nucleic Acid Amplification Tests (NAAT), and Others}, Immunodiagnostics, Microbial Cultures, and Others), Test Type (Laboratory-Based Tests and Point-of-Care (POC) Tests), Application (Viral Diseases, Bacterial Diseases, and Others), End-Users (Hospitals, Diagnostic Labs, and Others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing Infectious Disease Diagnostics market.

The infectious disease diagnostics comprises diagnostic tests, assays, instruments, and others that are utilized for the detection and identification of causative agents responsible for the disease.

The rising prevalence of infectious diseases such as tuberculosis, influenza, hepatitis, HIV/AIDS, COVID-19, dengue, malaria, and other emerging viral and bacterial infections is significantly increasing the global demand for rapid, reliable, and accurate diagnostic solutions. The growing burden of both chronic and acute infectious diseases has intensified the need for early diagnosis to prevent disease transmission, improve patient outcomes, and reduce healthcare costs. In addition, frequent outbreaks of emerging and re-emerging pathogens, coupled with increasing global travel and urbanization, are further accelerating the requirement for efficient infectious disease surveillance and testing systems across hospitals, diagnostic laboratories, clinics, and home-care settings.

Simultaneously, rising awareness among patients, healthcare professionals, and public health organizations regarding the importance of early disease detection and preventive healthcare is supporting the wider adoption of infectious disease diagnostic tests. Governments and international health agencies are increasingly implementing large-scale screening initiatives, vaccination monitoring programs, public health campaigns, and disease surveillance strategies to control infection spread and strengthen healthcare preparedness. These initiatives are particularly prominent in developing economies where improving healthcare access and diagnostic infrastructure are becoming major priorities.

Moreover, continuous product development and technological advancements by diagnostic manufacturers are transforming the infectious disease diagnostics landscape. Companies are actively introducing advanced molecular diagnostic technologies such as PCR-based assays, next-generation sequencing (NGS), multiplex testing platforms, AI-enabled diagnostic systems, automated analyzers, and rapid point-of-care testing kits that offer faster turnaround times, improved sensitivity, and higher diagnostic accuracy. The increasing integration of digital health technologies and portable diagnostic devices is also enhancing accessibility to testing in remote and resource-limited settings. Collectively, these factors are driving substantial growth in the infectious disease diagnostics market by increasing testing volumes, improving healthcare infrastructure, enabling timely clinical decision-making, and supporting effective disease management across both developed and emerging regions.

What are the latest infectious disease diagnostics market dynamics and trends?

The rising prevalence of infectious diseases, coupled with increased awareness and screening programs, is driving the demand for timely and accurate diagnostic solutions. As more people undergo regular testing, the need for reliable diagnostic tools grows. Additionally, the increase in product development activities worldwide is leading to advancements in diagnostic technologies, enhancing test accuracy, speed, and accessibility.

According to the latest stats provided by the World Health Organization

• Tuberculosis (TB): In 2024, an estimated 10.7 million people fell ill with TB worldwide. Diagnostics play a crucial role in quickly identifying active TB cases, enabling prompt treatment and reducing transmission risk. Screening for latent TB infection (LTBI) with tools like tuberculin skin tests and interferon-gamma release assays helps prevent disease activation. Molecular techniques like NAATs ensure rapid detection, including drug-resistant strains, guiding appropriate treatment, thereby boosting the infectious disease diagnostics market.
• Hepatitis: In 2022, an estimated 254 million people were living with hepatitis B and 50 million people were living with hepatitis C worldwide, and 6000 people were newly infected with viral hepatitis each day. Infectious disease diagnostics enable the early detection of hepatitis (types A, B, C, D, and E), often before symptoms appear. Early diagnosis is critical for preventing disease progression and reducing transmission. Blood tests, liver function tests, and serological tests identify specific hepatitis viruses by detecting antigens, antibodies, or viral genetic material (e.g., HBV DNA or HCV RNA) and thereby escalate the overall market of infectious disease diagnostics across the globe.
• HIV: In 2024, approximately 1.3 million [1.0-1.7 million] people acquired HIV across the world. HIV diagnostic tests are often bundled with tests for other sexually transmitted infections (STIs) like syphilis and hepatitis. Integrated testing increases the need for multi-disease diagnostic platforms.
• Influenza: In 2024, there were around a billion cases of seasonal influenza annually, including 3-5 million cases of severe illness. Influenza is diagnosed using rapid influenza diagnostic tests (RIDTs) for quick results, while advanced methods like RT-PCR and other nucleic acid amplification tests (NAATs) offer higher accuracy. Additionally, viral culture and serological tests help confirm infections and study immune responses.

Thus, the development of rapid diagnostic tests (RDTs), nucleic acid amplification tests (NAATs), and point-of-care (POC) testing has improved accessibility and accuracy, driving market growth. Additionally, the rise of antimicrobial resistance has pushed healthcare systems to prioritize early pathogen identification, ensuring timely interventions. The integration of diagnostics into routine health checkups and the growing trend of multiplex testing have further amplified the infectious disease diagnostics market.

Additionally, the increasing product development activities are further boosting the overall market of infectious disease diagnostics. In January 2025, OraSure Technologies, Inc., a leader in point-of-need and home diagnostic tests and sample management solutions, announced that the Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration (FDA) had approved a labeling change to the OraQuick(R) HIV Self-Test, increasing access to HIV testing for adolescents.

Thus, the factors mentioned above are expected to boost the overall market of infectious disease diagnostics during the forecast period.

However, the risk of sample contamination during transport and storage is a major limiting factor for the infectious disease diagnostics market, as it can reduce the accuracy and reliability of test results, leading to false positives, false negatives, or inconclusive outcomes. Improper handling, inadequate packaging, temperature fluctuations, poor sterilization practices, and weak cold chain management can damage sample integrity and affect diagnostic performance, especially in molecular tests such as PCR. In addition, long transportation times, inconsistent handling protocols, and limited healthcare infrastructure in developing regions further increase contamination risks. These challenges can delay disease detection, increase operational costs, and reduce trust in diagnostic testing, thereby hindering market growth during the forecast period.

Infectious Disease Diagnostics Market Segment Analysis

Infectious Disease Diagnostics Market by Type (Products {Instruments and Reagents & Kits} and Services), Technology (Molecular Diagnostics {Polymerase chain reaction (PCR), DNA Sequencing and Next-Generation Sequencing (NGS), Nucleic Acid Amplification Tests (NAAT), and Others}, Immunodiagnostics, Microbial Cultures, and Others), Test Type (Laboratory-Based Tests and Point-of-Care (POC) Tests), Application (Viral Diseases, Bacterial Diseases, and Others), End-Users (Hospitals, Diagnostic Labs, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Infectious Disease Diagnostics Market Regional Analysis

North America Infectious Disease Diagnostics Market Trends

North America is expected to account for the highest proportion of 41% of the infectious disease diagnostics market in 2025, out of all regions. North America is expected to dominate the infectious disease diagnostics market due to the high prevalence of infectious diseases, strong presence of leading diagnostic companies, advanced healthcare infrastructure, and increased adoption of molecular and point-of-care diagnostic technologies. In addition, favorable government initiatives, high healthcare spending, rising awareness regarding early disease detection, and continuous research and product development activities are further supporting market growth across the region.

As per the data provided by the U.S Department of Health and Human Services (2025), it was stated that about 23 million Americans visit a doctor's office or clinic seeking treatment for infections every year.

Additionally, according to the Centers for Disease Control and Prevention (2026), with more than 1.2 million Americans estimated to be living with HIV and nearly 39,000 diagnoses in 2024 in the U.S., the increasing prevalence of infectious diseases like viral flu, HIV, and hepatitis B in the United States will drive higher demand for infectious disease diagnostic testing. More cases require timely detection for effective treatment and containment, leading to increased testing in hospitals, clinics, and laboratories. Advancements in diagnostic technologies, along with public health initiatives, will further boost the need for rapid and accurate testing to prevent outbreaks and improve patient outcomes.

Moreover, various product development and launch activities in the domain of infectious disease diagnostics will further propel the market growth. In December 2023, QuidelOrtho Corporation announced that it had received 510(k) clearance from the U.S. FDA for its Savanna PCR platform and Savanna HSV 1+2/VZV test, enabling the detection and differentiation of HSV-1, HSV-2, and VZV from lesion swabs. This clearance allowed QuidelOrtho to market the platform and assay to U.S. labs performing moderate or high complexity diagnostic testing.

Thus, all the above-mentioned factors are anticipated to propel the market for infectious disease diagnostics in the United States during the forecast period from 2026 to 2034.

Europe Infectious Disease Diagnostics Market Trend

The Infectious Disease Diagnostics market in Europe is witnessing strong and sustained growth due to the rising prevalence of infectious diseases, increasing government focus on disease surveillance, and growing adoption of advanced molecular and point-of-care diagnostic technologies. The region benefits from well-established healthcare infrastructure, favorable reimbursement policies, and strong investments in research and development activities. In addition, the increasing burden of hospital-acquired infections (HAIs), antimicrobial resistance, and the growing demand for rapid and accurate diagnostic solutions are further supporting market expansion across Europe. The presence of leading diagnostic companies and continuous technological advancements in PCR, multiplex assays, and genomic testing are also accelerating market growth. Furthermore, recent product approvals and launches are strengthening the regional market. For instance, in September 2024, QIAGEN received European IVDR certification for its QIAstat-Dx syndromic testing systems and respiratory and gastrointestinal infection panels in Europe. Similarly, in 2024, Roche Diagnostics received CE marking for a new multiplex respiratory panel for detecting influenza, RSV, and SARS-CoV-2 variants. These developments are collectively boosting the growth of the infectious disease diagnostics market in Europe.

Asia-Pacific Infectious Disease Diagnostics Market Trends

The Asia Pacific (APAC) region is emerging as a major growth driver for the Infectious Disease Diagnostics market due to the rising prevalence of infectious diseases, growing population base, increasing healthcare expenditure, and improving access to diagnostic services across developing economies such as China, India, and Southeast Asian countries. Governments in the region are actively strengthening disease surveillance systems and investing in healthcare infrastructure to improve early disease detection and outbreak management. In addition, increasing awareness regarding infectious disease screening, expanding adoption of molecular diagnostics and point-of-care testing, and the growing presence of international as well as domestic diagnostic manufacturers are further accelerating market growth. Rapid urbanization, rising medical tourism, and supportive public health initiatives aimed at controlling diseases such as tuberculosis, dengue, hepatitis, influenza, and COVID-19 are also contributing significantly to the expansion of the infectious disease diagnostics market in the APAC region.

Who are the major players in the infectious disease diagnostics market?

The following are the leading companies in the infectious disease diagnostics market. These companies collectively hold the largest market share and dictate industry trends.

• Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• QIAGEN
• bioMerieux
• Siemens Healthineers AG
• DiaSorin S.p.A.
• Hologic, Inc.
• Sysmex Corporation
• QuidelOrtho Corporation
• Biosynex SA
• Cardinal Health
• Laboratory Corporation of America Holdings
• Eurofins Scientific
• InfeXn Laboratories Pvt Ltd.
• Aegis Sciences Corporation
• Meridian Bioscience, Inc.
• BD
• OraSure Technologies, Inc.
• Trinity Biotech plc
• Chembio Diagnostics, Inc.
• Sekisui Diagnostics
• PerkinElmer, Inc.
• GenMark Diagnostics, Inc.
• Seegene Inc.
• Fujirebio Holdings, Inc.
• Arkray, Inc.
• SD Biosensor, Inc.
• Mylab Discovery Solutions Pvt. Ltd.
• Molbio Diagnostics Pvt. Ltd.
• GenBody Inc.
• Others

How is the competitive landscape shaping the Infectious Disease Diagnostics market?

The competitive landscape of the infectious disease diagnostics market is highly dynamic and characterized by strong competition among global and regional players focusing on technological innovation, product development, strategic collaborations, mergers & acquisitions, and geographic expansion. Major companies such as F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., QIAGEN N.V., and bioMerieux SA are actively investing in advanced molecular diagnostics, multiplex assays, PCR technologies, and point-of-care testing solutions to strengthen their market presence. Companies are also emphasizing rapid and automated diagnostic platforms to improve testing accuracy, reduce turnaround time, and support large-scale disease screening. In addition, increasing regulatory approvals, partnerships with healthcare institutions, and expansion into emerging economies are intensifying market competition. The growing focus on AI-integrated diagnostics, syndromic testing panels, and decentralized testing solutions is further shaping the competitive environment and driving innovation across the infectious disease diagnostics market.

Recent Developmental Activities in the Infectious Disease Diagnostics Market

• In January 2025, OraSure Technologies, Inc., a leader in point-of-need and home diagnostic tests and sample management solutions, announced that the Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration (FDA) had approved a labeling change to the OraQuick(R) HIV Self-Test, increasing access to HIV testing for adolescents.

Infectious Disease Diagnostics Market Segmentation

• Infectious Disease Diagnostics by Type Exposure
• Products
• Instruments
• Reagents & Kits
• Services
• Infectious Disease Diagnostics by Technology Exposure
• Molecular Diagnostics
• Polymerase chain reaction (PCR)
• DNA Sequencing and Next-Generation Sequencing (NGS)
• Nucleic Acid Amplification Tests (NAAT)
• Others
• Immunodiagnostics
• Microbial Cultures
• Others
• Infectious Disease Diagnostics Test Type Exposure
• Laboratory Based Tests
• Point-of-Care (POC) Tests
• Infectious Disease Diagnostics Application Exposure
• Viral Diseases
• Bacterial Diseases
• Others
• Infectious Disease Diagnostics End-Users Exposure
• Hospitals
• Diagnostic Labs
• Others
• Infectious Disease Diagnostics Geography Exposure
• North America Infectious Disease Diagnostics Market
• United States Infectious Disease Diagnostics Market
• Canada Infectious Disease Diagnostics Market
• Mexico Infectious Disease Diagnostics Market
• Europe Infectious Disease Diagnostics Market
• United Kingdom Infectious Disease Diagnostics Market
• Germany Infectious Disease Diagnostics Market
• France Infectious Disease Diagnostics Market
• Italy Infectious Disease Diagnostics Market
• Spain Infectious Disease Diagnostics Market
• Rest of Europe Infectious Disease Diagnostics Market
• Asia-Pacific Infectious Disease Diagnostics Market
• China Infectious Disease Diagnostics Market
• Japan Infectious Disease Diagnostics Market
• India Infectious Disease Diagnostics Market
• Australia Infectious Disease Diagnostics Market
• South Korea Infectious Disease Diagnostics Market
• Rest of Asia-Pacific Infectious Disease Diagnostics Market
• Rest of the World Infectious Disease Diagnostics Market
• South America Infectious Disease Diagnostics Market
• Middle East Infectious Disease Diagnostics Market
• Africa Infectious Disease Diagnostics Market

Key takeaways from the infectious disease diagnostics market report study

• Market size analysis for the current infectious disease diagnostics market size (2025), and market forecast for 8 years (2026 to 2034)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the infectious disease diagnostics market.
• Various opportunities available for the other competitors in the infectious disease diagnostics market space.
• What are the top-performing segments in 2025? How these segments will perform in 2034?
• Which are the top-performing regions and countries in the current infectious disease diagnostics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the infectious disease diagnostics market growth in the future.

Frequently Asked Questions for the Infectious Disease Diagnostics Market

1. What is the growth rate of the infectious disease diagnostics market?

• The infectious disease diagnostics market is estimated to grow at a CAGR of 3.41% during the forecast period from 2026 to 2034.

2. What is the market for infectious disease diagnostics?

• The global infectious disease diagnostics market is expected to increase from USD 28,338.85 million in 2025 to USD 38,155 million by 2034.

3. Which region has the highest share in the infectious disease diagnostics market?

• North America is expected to dominate the infectious disease diagnostics market due to the high prevalence of infectious diseases, strong presence of leading diagnostic companies, advanced healthcare infrastructure, and increased adoption of molecular and point-of-care diagnostic technologies. In addition, favorable government initiatives, high healthcare spending, rising awareness regarding early disease detection, and continuous research and product development activities are further supporting market growth across the region.

4. What are the drivers for the infectious disease diagnostics market?

• The rising prevalence of infectious diseases such as tuberculosis, influenza, hepatitis, HIV, and emerging viral infections is significantly increasing the demand for rapid and accurate diagnostic solutions worldwide. At the same time, growing awareness among patients and healthcare providers, along with government-led screening and surveillance programs, is encouraging early disease detection and routine testing, thereby expanding the adoption of infectious disease diagnostics. In addition, continuous product development activities by diagnostic companies, including the launch of advanced molecular diagnostics, point-of-care testing kits, AI-enabled platforms, and multiplex assays, are improving testing accuracy, speed, and accessibility. Collectively, these factors are driving the growth of the infectious disease diagnostics market by increasing testing volumes, enhancing healthcare infrastructure, and supporting timely disease management across both developed and emerging regions.

5. Who are the key players operating in the infectious disease diagnostics market?

• Some of the key market players operating in the infectious disease diagnostics market include Hoffmann-La Roche Ltd., Abbott Laboratories, Bio-Rad Laboratories, Inc., Danaher Corporation, Thermo Fisher Scientific Inc., QIAGEN, bioMerieux, Siemens Healthineers AG, DiaSorin S.p.A., Hologic, Inc., Sysmex Corporation, QuidelOrtho Corporation, Biosynex SA, Cardinal Health, Laboratory Corporation of America Holdings, Eurofins Scientific, InfeXn Laboratories Pvt Ltd., Aegis Sciences Corporation, Meridian Bioscience, Inc., BD, OraSure Technologies, Inc., Trinity Biotech plc, Chembio Diagnostics, Inc., Sekisui Diagnostics, PerkinElmer, Inc., GenMark Diagnostics, Inc., Seegene Inc., Fujirebio Holdings, Inc., Arkray, Inc., SD Biosensor, Inc., Mylab Discovery Solutions Pvt. Ltd., Molbio Diagnostics Pvt. Ltd., GenBody Inc., and others.